This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

GPs buried under trusts' workload dump

GPs should use spirometry and FeNO tests to diagnose asthma, says NICE

GPs should carry out objective testing to diagnose suspected asthma, rather than simply relying on symptoms, suggest new guidelines from NICE published today.

The new guideline recommends spirometry and forced exhaled nitric oxide (FeNO) testing are used by GPs - where available - alongside the usual clinical assessment of symptoms, saying it will make diagnosis more accurate and treatment more effective.

The guideline rejects the recommendations from recently updated gold-standard BTS/SIGN guidelines to confirm a diagnosis of asthma based on a trial of treatment. 

It also recommends adding an leukotriene receptor antagonist (LTRA) tablets as the first-line add-on therapy for patients whose asthma is not controlled on inhaled steroids alone, as it claims they are are cheaper and therefore more cost-effective.This diverges significantly from the BTS/SIGN recommendation to offer a long-acting beta agonist (LABA) first.

NICE said its initial draft diagnostic recommendations were designed to tackle the third of patients which could be misdiagnosed with asthma. But it met with harsh criticism from both the BMA and the RCGP when first published in in 2015 on the basis that they were too complex and would lead to increased GP appointments, referrals and costs.

In addition, respiratory experts voiced concern over the addition of LTRAs to treatment guidelines, saying that it could 'cost lives' as patients may neglect their steriod inhalers.

In response, NICE took the unprecedented step of delaying publication of the guidelines to pilot the changes and discuss their implementation with NHS England.

A recent study did find that spirometry testing was 'useful' for asthma reviews in children in primary care, but GP experts say NICE's approach is 'not fit for purpose'.

Dr Dermot Ryan, GP and president of the international Respiratory Effectiveness Group, told Pulse the guideline was 'setting GPs up for failure'.

He said: 'It is really important that patients with asthma receive a proper diagnosis but the overconcentration on one parameter – in this case FeNO – is neither here nor there. Most GPs don’t have access to FeNO and most CCGs don’t have the funds or the know-how to invest in it.'

He went on to suggest that the guideline was 'being done purely for cost minimisation' adding: 'This should be resisted and it won’t save money. It’s not for no reason that guidelines elsewhere in the world recommend a LABA as the first add-on to inhaled corticosteroid. Really this guideline is not fit for purpose.’

Dr Duncan Keeley, GP and policy lead for the Primary Care Respiratory Society, said they were 'concerned at the potential for confusion'.

He said: ‘NICE is an excellent organisation, but PCRS UK has always questioned the wisdom of seeking to replace the widely respected BTS / SIGN guideline for asthma - which was itself approved by NICE. We identified major potential difficulties in implementation of the recommendations in the NICE guideline - views shared by many other organisations in the respiratory field - and we advised against its publication.

'We would encourage NICE and BTS/SIGN to cooperate on a single guideline in future. We will provide advice in the meanwhile to the primary care community about how to reconcile the conflicting guideline advice that we now have.’

The NICE guideline does acknowledge that it recommends a 'significant enhancement to current practice, which will take the NHS some time to implement'.

It adds: 'The investment and training required to implement the new guidance will take time. In the meantime, primary care services should implement what they can of the new guidelines, using currently available approaches to diagnosis until the infrastructure for objective testing is in place.’

BMA GP Committee prescribing lead Dr Andrew Green said the new NICE guidance on asthma was a 'significant change', but it was pleased that both NHS England and NICE recognise additional investment was be required to make these changes happen with diagnostic facilities in 'local hubs'.

He added: 'Their statement that GPs should continue with current diagnostic methods during the transition period is vital both to protect GPs and to ensure system stability.'

RCGP Clinical Innovation and Research Centre joint medical director Dr Imran Rafi said: 'We still have concerns about the capacity, cost and training implications of implementing FeNO testing as standard in general practice – in this respect it is encouraging that the guidelines include the caveat that this is unlikely to be implemented until GPs are appropriately resourced to deliver it.

'There is also the issue that the addition of Leukotriene Receptor Agonists (LTRAs) as a treatment could lead to patients inadvertently stopping their use of inhaled corticosteroids, particularly when not prescribed as a combination inhaler with long-acting bronchodilators. Patients will need to be reminded about this.'

Dr Rafi added that it was 'important to remember that they are not tramlines and GPs must retain the freedom to develop treatment plans based on the unique circumstances of the patient in front of us'.

Related images

  • COPD nurse consultation inhaler technique PPL

Readers' comments (17)

  • Should we not rename this organization yearning for the absurd as 'UGLY' ( Utterly, gutterly, d*kheaded yearner)?

    Unsuitable or offensive? Report this comment

  • Here is the best NICE guideline:

    1 Avoid everything issued by NICE because it is impractical rubbish.

    2 Go back to 1

    Unsuitable or offensive? Report this comment

  • I am going to disagree with the comments of my colleagues on this.
    LTRAs are cheap, but they are also safe and simple, a tablet a day. They also help rhinitis which is often present if you care to ask.
    They are a great way to improve compliance and control; I often use them with a step down strategy of the inhaled steroids, which are often used at unnecessarily high doses. For most patient ICS have a flat response curve.

    And when maybe 1 in 3 patients are given the diagnosis of a disease that they dont have for the want of a simple breath test, why wouldnt GPs want FeNO?
    IMO we should have it already. There too much dumbing down of General Practice. We should be given the tools to do our job properly.

    Unsuitable or offensive? Report this comment

  • John, that is the point, we should be given the tools to do our jobs correctly: This means, resources, staff, premises, consumables etc.....presently all of the above are being kept from us in primary care so what do we do when secondary care seem to be getting all the current investment from HMG, we are down to 5.5% total NHS funding for primary care in general practice, how far further can it drop as millions more are pumped into secondary care to deal with waiting lists and hospital winter pressures......

    Unsuitable or offensive? Report this comment

  • If NICE thinks this will save money, think again. Especially as there now need to be ‘competencies’ in spirometry. This will lead to more referrals to secondary care.

    Unsuitable or offensive? Report this comment

  • NICE : No Iota of Commonsense Exists!!

    Unsuitable or offensive? Report this comment

  • It's not a big issue. If we need a better diagnostic method and feno is it then that's that. Just a quick letter to refer. Can't see the problem.

    Unsuitable or offensive? Report this comment

View results 10 results per page20 results per page

Have your say